Outlook Therapeutics appoints Robert C. Jahr as President and CEO, replacing interim CEO

Outlook Therapeutics, Inc.

Robert C. Jahr appointed President & CEO effective July 1, 2025; replaces interim CEO Lawrence Kenyon, who remains CFO and board member.
Base salary $600,000; target annual bonus 70% of base; inducement option for 800,000 shares vesting over 4 years.
Jahr previously Chief Commercial Officer at Sobi NA (2021-2025); held leadership roles at UCB Pharma and Amgen.
Severance: 12 months base salary + target bonus on qualifying termination; 18 months base + 150% bonus on termination in connection with change in control.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.